FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128794616> ?p ?o ?g. }

• W2128794616 endingPage "719" @default.
• W2128794616 startingPage "711" @default.
• W2128794616 abstract "Colorectal cancer patients with BRAF-mutant tumors have a more aggressive, rapidly progressing disease that is in critical need of novel therapeutic approaches. Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving standard-of-care therapy is approximately two years or more if their tumors express wild-type BRAF and wild-type KRAS, median OS is less than twelve months with tumors expressing V600E-mutant BRAF and wild-type KRAS. Pro-apoptotic receptor agonists are a class of biologic agents under development to induce tumor-specific apoptosis and are being combined with classical chemotherapy or targeted agents in clinical trials. Herein, we present the case of a patient with bulky V600E-mutant BRAF hepatic flexure colon carcinoma, treated initially with FOLFOX plus bevacizumab neoadjuvant therapy and surgery. The patient had a rapid tumor relapse with metastatic disease to the liver and lung, and was enrolled in a phase 1b open-label clinical study, where he received the FOLFIRI regimen in combination with the pro-apoptotic receptor agonist dulanermin (rhApo2L/TRAIL). The patient maintained stable disease through 25 doses administered every two weeks before his disease progressed. After coming off study, the patient underwent surgical debulking and received intraperitoneal hyperthermic chemotherapy. He subsequently relapsed and was treated with FOLFIRI plus cetuximab. At the time of this report, the patient remains on active treatment. It is unclear what effect dulanermin may have had on the course of his disease, but it is noteworthy that the patient remained on FOLFIRI plus dulanermin therapy for a period that exceeded the median OS for patients with advanced, aggressive BRAF-mutant CRC. It is also noteworthy that at the time of this report the patient's overall survival since diagnosis has exceeded 30 months, which is beyond what is generally observed even for patients with CRC harboring wild-type BRAF and wild-type KRAS." @default.
• W2128794616 created "2016-06-24" @default.
• W2128794616 creator A5028133447 @default.
• W2128794616 creator A5028789154 @default.
• W2128794616 creator A5036572092 @default.
• W2128794616 creator A5040371543 @default.
• W2128794616 creator A5040899413 @default.
• W2128794616 creator A5051892896 @default.
• W2128794616 creator A5053893309 @default.
• W2128794616 creator A5075201353 @default.
• W2128794616 creator A5082007373 @default.
• W2128794616 creator A5089833624 @default.
• W2128794616 date "2013-08-12" @default.
• W2128794616 modified "2023-10-18" @default.
• W2128794616 title "FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer" @default.
• W2128794616 cites W1515354111 @default.
• W2128794616 cites W1837825273 @default.
• W2128794616 cites W1970856815 @default.
• W2128794616 cites W1973468487 @default.
• W2128794616 cites W1975221809 @default.
• W2128794616 cites W1975807921 @default.
• W2128794616 cites W2007420407 @default.
• W2128794616 cites W2010948762 @default.
• W2128794616 cites W2041360135 @default.
• W2128794616 cites W2041742567 @default.
• W2128794616 cites W2047657908 @default.
• W2128794616 cites W2056217426 @default.
• W2128794616 cites W2059518503 @default.
• W2128794616 cites W2087877138 @default.
• W2128794616 cites W2106284224 @default.
• W2128794616 cites W2113505777 @default.
• W2128794616 cites W2125229905 @default.
• W2128794616 cites W2135800465 @default.
• W2128794616 cites W2144824249 @default.
• W2128794616 cites W2152247516 @default.
• W2128794616 cites W2170523250 @default.
• W2128794616 doi "https://doi.org/10.4161/cbt.25310" @default.
• W2128794616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3841210" @default.
• W2128794616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23792567" @default.
• W2128794616 hasPublicationYear "2013" @default.
• W2128794616 type Work @default.
• W2128794616 sameAs 2128794616 @default.
• W2128794616 citedByCount "11" @default.
• W2128794616 countsByYear W21287946162014 @default.
• W2128794616 countsByYear W21287946162016 @default.
• W2128794616 countsByYear W21287946162018 @default.
• W2128794616 countsByYear W21287946162019 @default.
• W2128794616 countsByYear W21287946162020 @default.
• W2128794616 countsByYear W21287946162023 @default.
• W2128794616 crossrefType "journal-article" @default.
• W2128794616 hasAuthorship W2128794616A5028133447 @default.
• W2128794616 hasAuthorship W2128794616A5028789154 @default.
• W2128794616 hasAuthorship W2128794616A5036572092 @default.
• W2128794616 hasAuthorship W2128794616A5040371543 @default.
• W2128794616 hasAuthorship W2128794616A5040899413 @default.
• W2128794616 hasAuthorship W2128794616A5051892896 @default.
• W2128794616 hasAuthorship W2128794616A5053893309 @default.
• W2128794616 hasAuthorship W2128794616A5075201353 @default.
• W2128794616 hasAuthorship W2128794616A5082007373 @default.
• W2128794616 hasAuthorship W2128794616A5089833624 @default.
• W2128794616 hasBestOaLocation W21287946161 @default.
• W2128794616 hasConcept C104317684 @default.
• W2128794616 hasConcept C121608353 @default.
• W2128794616 hasConcept C126322002 @default.
• W2128794616 hasConcept C143998085 @default.
• W2128794616 hasConcept C184235292 @default.
• W2128794616 hasConcept C185592680 @default.
• W2128794616 hasConcept C2776470698 @default.
• W2128794616 hasConcept C2776694085 @default.
• W2128794616 hasConcept C2776705615 @default.
• W2128794616 hasConcept C2777802072 @default.
• W2128794616 hasConcept C2778260052 @default.
• W2128794616 hasConcept C2778332735 @default.
• W2128794616 hasConcept C2778472372 @default.
• W2128794616 hasConcept C2779998722 @default.
• W2128794616 hasConcept C2780259306 @default.
• W2128794616 hasConcept C2780427987 @default.
• W2128794616 hasConcept C2780962732 @default.
• W2128794616 hasConcept C2781100745 @default.
• W2128794616 hasConcept C2781187634 @default.
• W2128794616 hasConcept C2781249067 @default.
• W2128794616 hasConcept C501734568 @default.
• W2128794616 hasConcept C526805850 @default.
• W2128794616 hasConcept C55493867 @default.
• W2128794616 hasConcept C57074206 @default.
• W2128794616 hasConcept C71924100 @default.
• W2128794616 hasConcept C86803240 @default.
• W2128794616 hasConcept C95444343 @default.
• W2128794616 hasConceptScore W2128794616C104317684 @default.
• W2128794616 hasConceptScore W2128794616C121608353 @default.
• W2128794616 hasConceptScore W2128794616C126322002 @default.
• W2128794616 hasConceptScore W2128794616C143998085 @default.
• W2128794616 hasConceptScore W2128794616C184235292 @default.
• W2128794616 hasConceptScore W2128794616C185592680 @default.
• W2128794616 hasConceptScore W2128794616C2776470698 @default.
• W2128794616 hasConceptScore W2128794616C2776694085 @default.
• W2128794616 hasConceptScore W2128794616C2776705615 @default.
• W2128794616 hasConceptScore W2128794616C2777802072 @default.

• next